Teverelix
| Code | Size | Price |
|---|
| TAR-T28954-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Teverelix is a water-soluble antagonist of luteinizing hormone-releasing hormone (LHRH).
CAS:
151272-78-5
Formula:
C74H100ClN15O14
Molecular Weight:
1459.16
Purity:
0.98
SMILES:
CC(C)C[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
References
1. Erb K, Pechstein B, Schueler A, Engel J, Hermann R. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. Clin Pharmacol Ther. 2000 Jun;67(6):660-9. PubMed PMID: 10872648.
2. Schneider A, Lang A, Naumann W. Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix. J Fluoresc. 2010 Nov;20(6):1233-40. doi: 10.1007/s10895-010-0674-5. Epub 2010 Jun 1. PubMed PMID: 20514551.
3. Sorensen S, Rondeau JJ, Lenaerts V, Boutignon F, W?thrich P, Deghenghi R, Adam A, Ong H. Radioimmunoassay of Antarelix, a luteinizing hormone releasing-hormone antagonist, in plasma and its application for pharmacokinetic study in dogs. J Immunoassay. 1996 Aug;17(3):205-26. PubMed PMID: 8842981.
4. Briant C, Ottogalli M, Morel M, Guillaume D. Use of a GnRH antagonist, antarelix, associated or not with hCG, to control ovulation in cyclic pony mares. Domest Anim Endocrinol. 2003 May;24(4):305-22. PubMed PMID: 12742549.